Sterling Products built a drug empire on a rival's trademark, bought at auction

the problem

Building a nationally trusted pharmaceutical brand from scratch takes decades most companies can't front

background

what everyone would do

Invest in Sterling Products' own research and development to create competing drug formulations, build brand recognition gradually through advertising and word of mouth over years, and compete against Bayer's established reputation the conventional way, through better products or better marketing rather than acquiring the rival's own name.

what they saw

Sterling Products didn't invent aspirin or build the Bayer brand — it bought both, seized from a wartime enemy and auctioned by the US government for $5.3 million in a single afternoon.

the move

The auction converted decades of Bayer's German-built brand investment, chemical research, trademark recognition, consumer trust, into a single transferable asset a competitor could simply purchase from the US government rather than build independently. Sterling Products, which had no comparable pharmaceutical research infrastructure of its own, used the acquired Bayer name and Aspirin trademark to become one of the dominant firms in the American over-the-counter drug market for decades afterward, eventually growing into Sterling Drug. The transaction later became the subject of extended litigation, including United States v. Chemical Foundation, 5 F.2d 191 (3d Cir. 1925), which examined the legality of the wartime seizure and sale process, and decades later Sterling Drug, Inc. v. Bayer AG, litigation in the 1990s over the German Bayer company's attempts to reclaim rights to its own name in North American markets it had been legally separated from since 1918. The case remains a documented example in trademark and business history of how wartime government intervention can instantly transfer an entire brand's accumulated value from one company to a direct competitor, entirely independent of either company's ordinary commercial performance.

why it works

The mechanism worked because wartime property seizure created a genuinely unique transaction structure ordinary markets don't offer: a government agency, not the original brand owner, controlled the sale, and national security and reparations logic rather than the brand owner's willingness determined that a sale would happen at all. This meant an asset that would never voluntarily have been sold by Bayer became available to the highest bidder, and any company with sufficient capital and speed, not necessarily the most innovative or the largest, could win it.

the payoff

In 1918 Sterling bought Bayer's seized US trademarks, including Aspirin, at auction for $5.3M — instantly owning a famous drug brand.

where it breaks

This is not a repeatable acquisition strategy; it depended entirely on a specific, rare historical circumstance, wartime enemy-property seizure, that a company cannot create or predict, and building a strategy around waiting for equivalent opportunities would mean waiting indefinitely. The acquired brand also carried a permanent legal complication: it produced decades of subsequent litigation over trademark rights between the original German company and its US acquirer, a dispute a normally built brand would never face, since the underlying ownership was never fully resolved by ordinary commercial means.

what came after

The 1918 auction permanently split the Bayer name and Aspirin trademark between two unrelated companies in North America and Germany, a divide formalized in subsequent litigation including United States v. Chemical Foundation (1925) and Sterling Drug, Inc. v. Bayer AG (1990s), and remains a documented case study in how wartime property law can override ordinary trademark and brand-building economics.

references

1. [1]United States v. Chemical Foundation, 5 F.2d 191 (3d Cir. 1925)US Court of Appeals for the Third Circuit (Justia), 1925law.justia.com
2. [2]Bayer patents aspirinHistory.com, 2020history.com

keep it